We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Glucose Levels May Predict Pneumonia Death Risk

By LabMedica International staff writers
Posted on 18 Jun 2012
Nondiabetic patients who have high blood glucose on admission for community-acquired pneumonia (CAP) are at significantly elevated risk for death and may benefit from intensified care.

There is a strong association between diabetes and cardiovascular disease that contributes to overall mortality from CAP and infection and acute hyperglycemia, related illnesses. More...


At the University Hospital of Saarland (Homburg, Germany) scientists carried out a prospective multicenter study on 6,891 patients from 12 clinical centers. The study began in July 2002, and was analyzed in December 2009. The mean age of participants was 59.8 ±18.5 years and 3,805 (55.2%) were men. Overall, 324 (4.7%) participants died within 28 days, 514 (7.5%) within 90 days, and 648 (9.4%) within 180 days. Overall mortality on days 28, 90, and 180 was significantly higher in participants with diabetes than without diabetes.

Higher serum glucose levels were associated with increased mortality in all patients. Mortality within 90 days increased in a stepwise manner in those with glucose concentrations of 108-197 mg/dL, 198-251 mg/dL, and equal or greater than 252 mg/dL when compared with patients with normal serum glucose concentrations of 72-107 mg/dL. Nondiabetics with normal blood glucose levels had the lowest 90-day mortality rate of 3%, while those with hyperglycemia had a mortality rate of 10%, and patients with diabetes had the highest death rate at 14%, irrespective of glucose levels on admission.

The authors concluded that patients with increased serum glucose levels or diabetes at the time of CAP was diagnosed were at significantly increased risk of death from the disease. Oral glucose tolerance test and close glucose monitoring after discharge are necessary to diagnose overt diabetes and to prevent subacute or long-term complications. The study was published on May 29, 2012, in the British Medical Journal (BMJ).

Related Links:
University Hospital of Saarland



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.